Investor Presentaiton
DNA
We updated our financial targets; EBITDA margin 34%
DNA has updated its' mid-term financial targets in part of EBITDA margin and dividend policy.
Target
2018
2017
2016
Net sales growth - faster than average market growth
EBITDA margin of at least 34%
31.2%
30.7%
27.5%
(earlier target 32%, new target includes IFRS16 impact¹)
Operative capital expenditure less than 15% of sales
14.7%
15.0%
15.9%
(excluding IFRS16 impact²)
Net debt/EBITDA less than 2.0 (can be temporarily exceeded in case of
potential attractive bolt-on in-market M&A opportunities)³
1.33x
1.12x
1.36x
DNA's profit distribution policy: DNA's goal is to pay a growing dividend to its shareholders or by other means to return
capital equaling 80-100 percent of the net profit of fiscal year. In addition, the Board of Directors may consider the distribution of
excess profit to shareholders for a specific financial period. When making the profit distribution decision, the Board of Directors
will take into account the company's financial status and financial position as well as future funding needs and financial goals.
IFRS 16 standard was adopted at the beginning of 2019, and it's estimated to have an impact in 2019 to our
1. EBITDA, of approximately EUR +17 million
2. Investments, of approximately EUR +8 million. Operative capital expenditure are investments excluding capitalized spectrum license payments.
3. Net debt to EBITDA, of approximately +0,2
DNA's Investor presentation, February 2019
38View entire presentation